Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada
Authors
Keywords
-
Journal
CLINICAL DRUG INVESTIGATION
Volume 41, Issue 8, Pages 733-739
Publisher
Springer Science and Business Media LLC
Online
2021-07-21
DOI
10.1007/s40261-021-01059-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association between response to triptans and response to erenumab: real-life data
- (2021) Ilaria Frattale et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab patient characteristics, medication adherence, and treatment patterns in the United States
- (2021) Dionne M. Hines et al. HEADACHE
- Geography, generalisability, and susceptibility in clinical trials
- (2021) Jane E Clougherty et al. Lancet Respiratory Medicine
- Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine
- (2021) Fumihiko Sakai et al. HEADACHE
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
- (2020) Bianca Raffaelli et al. Frontiers in Neurology
- De Novo Visual Aura Onset in a Migraineur on Galcanezumab‐Gnlm
- (2020) Elizabeth Kearney et al. HEADACHE
- European headache federation consensus on the definition of resistant and refractory migraine
- (2020) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
- (2020) Antonio Russo et al. JOURNAL OF HEADACHE AND PAIN
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
- (2020) Armin Scheffler et al. JOURNAL OF HEADACHE AND PAIN
- Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
- (2020) Saad Kanaan et al. CEPHALALGIA
- Erenumab in Chronic Migraine: An Australian Experience
- (2020) Shuli Cheng et al. HEADACHE
- Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine
- (2020) Jennifer Robblee et al. HEADACHE
- Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study
- (2019) William B. Young et al. JOURNAL OF HEADACHE AND PAIN
- Therapeutic novelties in migraine: new drugs, new hope?
- (2019) Thien Phu Do et al. JOURNAL OF HEADACHE AND PAIN
- The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
- (2019) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
- (2018) Messoud Ashina et al. CEPHALALGIA
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
- (2018) Andrew M. Blumenfeld et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting
- (2017) Antonio Santoro et al. NEUROLOGICAL SCIENCES
- Therapeutic antibodies against CGRP or its receptor
- (2015) Marcelo E. Bigal et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment
- (2015) Lars Edvinsson BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Monoclonal Antibodies for Migraine: Preventing Calcitonin Gene-Related Peptide Activity
- (2014) Marcelo E. Bigal et al. CNS DRUGS
- Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
- (2014) David W Dodick et al. LANCET NEUROLOGY
- Opioid Use and Dependence Among Persons With Migraine: Results of the AMPP Study
- (2012) Dawn C. Buse et al. HEADACHE
- Critical role of calcitonin gene-related peptide receptors in cortical spreading depression
- (2012) A. Tozzi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search